FIELD: medicine.
SUBSTANCE: against the background of basic therapy with drugs that improve microcirculation, antispasmodics, antiplatelet agents and statins, additionally intravenously injected ozonized saline solution once a day in a volume of 400 ml with an ozone concentration of 2-4 mg/l. Then, not earlier than 4-6 hours, Vasaprostan® is administered - 60 mcg of alprostadil dissolved in 250 ml of a 0.9% solution of sodium chloride or Ringer's solution, with an infusion rate of 80 ml/h, with a course of 10 days.
EFFECT: application of the invention allows stabilizing the progression of the atherosclerotic process, increasing the walking distance and reducing the risk of developing critical ischemia.
1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING PATIENTS WITH OBLITERATING ARTERIAL SCLEROSIS OF LOWER EXTREMITIES COMBINED WITH ISCHEMIC HEART DISEASE | 2013 |
|
RU2525157C1 |
METHOD OF TREATING PATIENTS WITH OBLITERATING DISEASES OF LOWER EXTREMITY ARTERIES | 2013 |
|
RU2523412C1 |
THERAPY OF CHRONIC LOWER LIMB ISCHEMIA | 2008 |
|
RU2367477C1 |
THERAPY OF CHRONIC ARTERIAL LOWER LIMB ISCHEMIA | 2008 |
|
RU2364416C1 |
METHOD OF CRITICAL LOWER EXTREMITY ISCHEMIA TREATMENT | 2008 |
|
RU2357735C1 |
METHOD FOR TREATING PURULENT-NECROTIC LESIONS OF THE FEET IN PATIENTS WITH ISCHEMIC FORM OF DIABETIC FOOT SYNDROME | 2022 |
|
RU2805258C1 |
METHOD FOR TREATING CRITICAL ISCHEMIA OF INFERIOR LIMBS | 2001 |
|
RU2201262C2 |
METHOD OF TREATING OBLITERATING LOWER EXTREMITY ARTERY DISEASES | 2013 |
|
RU2523390C1 |
METHOD OF TREATING CHRONIC LOWER LIMB ISCHEMIA OF IIB - IV STAGES | 2007 |
|
RU2351334C1 |
METHOD FOR ASSESSING RISK OF PROGRESSIVE COURSE OF OBLITERATING ARTERIAL SCLEROSIS OF LOWER EXTREMITIES | 2015 |
|
RU2578968C1 |
Authors
Dates
2017-07-07—Published
2016-06-15—Filed